Vitamin K antagonists did not increase the risk of myelodysplastic syndrome in a large-scale cohort study

Blood. 2021 Aug 5;138(5):417-420. doi: 10.1182/blood.2021010848.

Authors

Anke Neumann¹, Marie-Joelle Jabagi¹, Mahmoud Zureik^{1

2}

Affiliations

¹ EPI-PHARE (Groupement d'Intérêt Scientifique), Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products, and French National Health Insurance), Saint-Denis, France; and.
² Versailles Saint-Quentin-en-Yvelines University, Versailles, France.

PMID: 33876243
DOI: 10.1182/blood.2021010848

No abstract available

Publication types

Comment

MeSH terms

Cohort Studies
Fibrinolytic Agents
Humans
Myelodysplastic Syndromes* / chemically induced
Myelodysplastic Syndromes* / epidemiology
Vitamin K*

Substances

Fibrinolytic Agents
Vitamin K